



## ASX Announcement

### Monash IVF Group Limited (ASX: MVF)

18 October 2017

#### **Monash IVF Group appoints Mr David Morris as the Chief Executive Officer (CEO) and Managing Director (MD)**

Monash IVF Group Ltd (ASX: MVF), a leading provider of assisted reproductive services (ARS) and specialist women's imaging and diagnostic services in Australia and Malaysia, is pleased to announce the appointment of Mr David Morris as the CEO and MD effective from 13 November 2017.

David has more than 20 years of leadership, international business development and strategy experience. Over his 13 years at Cochlear Limited, the global leader in implantable hearing solutions, which includes cochlear implants, bone conduction implants and middle ear implants, David served as Chief Strategy Officer, having previously served as President of Cochlear Bone Anchored Solutions and as Senior Vice President of Business Development.

Prior to joining Cochlear Limited, David worked at Accenture in the strategy practice. David has extensive experience internationally and domestically in the healthcare, consumer products, utilities, and financial services industries.

David holds degrees in Business and Applied Science from Monash University, Melbourne Australia. He has also completed an Advanced Business Management Program at Kellogg School of Management, Northwestern University in Chicago, USA and is a graduate of the Australian Institute of Company Directors.

MVF Chairman Richard Davis said; *"We are pleased to welcome someone with the nature of David's experience in healthcare, international business development and strategy setting and execution. We are confident that his leadership, skills and experience will be of significant benefit at a time where we continue to explore strategic growth opportunities domestically and in global markets"*.

MVF new CEO and MD David Morris said; *"I am honoured and excited to be working in such an innovative company that is at the forefront of fertility treatment. I look forward to leading Monash IVF Group through its next phase of growth, and to building further on its local and international success."*

The key terms and conditions of David's employment contract are outlined below:

<b>Terms</b>	<b>Details</b>
<b>Start Date</b>	13 November 2017
<b>Total Fixed Remuneration</b>	\$500,000 per annum including superannuation.
<b>Short Term Incentives</b>	The CEO and MD has the opportunity to earn an annual incentive of 60% of his fixed remuneration package based on meeting defined criteria.
<b>Long Term Incentives</b>	The CEO and MD has the opportunity to earn an annual incentive of 60% of his fixed remuneration package based on meeting defined criteria.
<b>Notice Period</b>	12 Months
<b>Term of Agreement</b>	No Fixed Term
<b>Restraint Period</b>	12 Months

Furthermore we confirm James Thiedeman will complete his role as the current CEO and MD on 10 November 2017.

**...Ends...**

**Investor enquiries:**

Richard Davis  
Chairman  
Monash IVF Group  
+61 3 9420 8235

Michael Knaap  
Chief Financial Officer and Company Secretary  
Monash IVF Group  
+61 3 9420 8235

**About Monash IVF Group**

Monash IVF Group is a leading provider of assisted reproductive services and specialist womens imaging and diagnostic services in Australia and Malaysia. The Group is a driving force in the development of assisted reproductive technologies and has many Australian and world firsts since the work of our pioneers who achieved the first IVF pregnancy in the world in 1973.